We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+66.65%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.82B
AUM Growth
-$64.9M
Cap. Flow
+$24.6M
Cap. Flow %
1.35%
Top 10 Hldgs %
65.19%
Holding
53
New
8
Increased
7
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$59.6M
2
JANX icon
Janux Therapeutics
JANX
+$55.5M
3
DRUG
Bright Minds Biosciences
DRUG
+$37.3M
4
OKUR
OnKure Therapeutics
OKUR
+$27.8M
5
BIOA
BioAge Labs
BIOA
+$17.2M

Top Sells

Rank Stock Value
1
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$93M
2
PCVX icon
Vaxcyte
PCVX
+$57.1M
3
BHVN icon
Biohaven
BHVN
+$16.2M
4
URGN icon
UroGen Pharma
URGN
+$15M
5
YMAB
Y-mAbs Therapeutics
YMAB
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.56B
$460M 25.26%
8,494,151
– –
PRAX icon
2
Praxis Precision Medicines
PRAX
$8.11B
$130M 7.16%
1,693,219
+823,219
+95% +$59.6M
JANX icon
3
Janux Therapeutics
JANX
$912M
$112M 6.17%
2,100,000
+1,050,000
+100% +$55.5M
ACLX
4
DELISTED
Arcellx
ACLX
$99.7M 5.48%
1,300,000
+50,000
+4% +$4.32M
EWTX icon
5
Edgewise Therapeutics
EWTX
$4.28B
$91M 5%
3,406,534
– –
NAMS icon
6
NewAmsterdam Pharma
NAMS
$3.26B
$83.5M 4.59%
3,250,000
+780,000
+32% +$16.6M
EYPT icon
7
EyePoint Inc
EYPT
$999M
$62M 3.41%
8,325,000
– –
RAPP
8
Rapport Therapeutics
RAPP
$1.96B
$52.2M 2.87%
2,940,921
– –
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$8.88B
$51.1M 2.81%
1,000,000
-100,000
-9% -$5.59M
INSM icon
10
Insmed
INSM
$22.4B
$44.9M 2.46%
650,000
+150,000
+30% +$10.8M
BBIO icon
11
BridgeBio Pharma
BBIO
$16.4B
$43.9M 2.41%
1,600,000
-258,351
-14% -$6.68M
CNTA
12
DELISTED
Centessa Pharmaceuticals
CNTA
$42.9M 2.36%
2,561,600
– –
DRUG
13
Bright Minds Biosciences
DRUG
$697M
$38.2M 2.1%
+1,059,331
New +$37.3M
PCVX icon
14
Vaxcyte
PCVX
$7.65B
$34.8M 1.91%
425,000
-575,000
-58% -$57.1M
MRUS
15
DELISTED
Merus
MRUS
$31.1M 1.71%
740,000
– –
BBOT
16
BridgeBio Oncology
BBOT
$659M
$30.5M 1.68%
2,909,000
– –
RNAM
17
DELISTED
Avidity Biosciences
RNAM
$30.5M 1.68%
1,050,000
– –
PHVS icon
18
Pharvaris
PHVS
$2.28B
$28.1M 1.54%
1,466,460
– –
CRBP icon
19
Corbus Pharmaceuticals
CRBP
$165M
$28M 1.54%
2,375,000
– –
TARS icon
20
Tarsus Pharmaceuticals
TARS
$2.55B
$27.7M 1.52%
500,000
– –
AXSM icon
21
Axsome Therapeutics
AXSM
$11.7B
$27.5M 1.51%
325,000
-75,000
-19% -$6.9M
ARQT icon
22
Arcutis Biotherapeutics
ARQT
$3.48B
$25.4M 1.4%
1,825,000
-500,000
-22% -$5.48M
RYTM icon
23
Rhythm Pharmaceuticals
RYTM
$7.31B
$22.4M 1.23%
400,000
– –
CGON icon
24
CG Oncology
CGON
$6.1B
$22.2M 1.22%
775,000
-200,000
-21% -$6.84M
CRGX
25
DELISTED
CARGO Therapeutics
CRGX
$17.1M 0.94%
1,182,563
– –
1
2 3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Cormorant Asset Management held 53 positions worth $1.82B, down 3.4% from $1.89B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Cormorant Asset Management's Q4 2024 filing shows 8 new, 7 increased, 11 reduced and 5 closed positions. Its largest new stake was Bright Minds Biosciences: 1,059,331 shares worth $38.2M. The largest sale was Longboard Pharmaceuticals, Inc. Common Stock, an estimated $93M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Cormorant Asset Management's largest Q4 2024 buy was Bright Minds Biosciences: 1,059,331 shares worth $38.2M.
  • Cormorant Asset Management added most to Praxis Precision Medicines in Q4 2024, an estimated $59.6M increase.
  • Cormorant Asset Management's biggest Q4 2024 reduction was Vaxcyte, cutting an estimated $57.1M.
  • Cormorant Asset Management fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q4 2024, selling an estimated $93M.
  • Cormorant Asset Management's ten largest holdings make up 65% of its $1.82B portfolio in Q4 2024.
  • Cormorant Asset Management opened 8 new positions and closed 5 in Q4 2024.
  • Cormorant Asset Management's portfolio value fell 3.4% quarter-over-quarter to $1.82B.

Based on Cormorant Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.